On Friday, June 21, 2024, the FDA updated its Patent Listing Dispute List to indicate that the ten pharmaceutical companies who had received warning letters from the FTC in April did not make changes to their patent listings...more
On March 20, 2024, The USPTO issued an alert, notifying practitioners that the USPTO had developed training materials for patent examiners regarding searching for prior art in FDA and NIH databases. ...more
3/25/2024
/ Biotechnology ,
Food and Drug Administration (FDA) ,
Healthcare ,
Intellectual Property Protection ,
National Institute of Health (NIH) ,
Over The Counter Drugs (OTC) ,
Patent Examinations ,
Pharmaceutical Industry ,
Prescription Drugs ,
Prior Art ,
Training Requirements ,
USPTO
On December 8, 2023, the U.S. Food and Drug Administration (FDA) approved two new gene therapies for the treatment of sickle cell disease. The first, Casgevy™ (exagamglogene autotemcel (exa-cel)), is the first-ever approved...more